Cancer Treatment News and Research

RSS

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

In a new study in which Precision Therapeutics' Multi-Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFx® in vitro chemosensitivity test and multi-gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens in breast cancer.

21 Jan 2011

Breastfeeding can partially offset long-term side effects of cancer treatment

Women who have survived childhood cancer should be advised to breastfeed if they can, in order to offset some of the negative health effects of their earlier cancer treatment. According to Susan Ogg and colleagues from St. Jude Children's Research Hospital in Memphis, Tennessee, making women aware of the benefits of breastfeeding should be part of routine post-cancer diet and healthy lifestyle recommendations.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

ETPN, Nanobiotix introduce Nanomed TV to provide information on Nanomedicine

Nanomed TV www.dailymotion.com/nanomedTV foresees to become the main hub for Nanomedicine thanks to its initiators, two major European players in nanomedicine: the European Technology Platform on Nanomedicine and Nanobiotix.

20 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Diabetes increases risk of death in breast cancer patients

Breast cancer patients are nearly 50 percent more likely to die of any cause if they also have diabetes, according to a comprehensive review of research conducted by Johns Hopkins physicians.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

The University of Illinois is set to receive a grant from the Friends of Mel Foundation (FOM) in support of their Bone Marrow Transplant Program. The program was selected as the recipient of the Mel's Magic award for January 2011. Mel's Magic was created by FOM in May 2009 to familiarize their supporters with other organizations that work tirelessly to make a difference in the cancer community.

14 Jan 2011

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

14 Jan 2011

20% of cancer survivors experience chronic pain: Study

Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.

13 Jan 2011

Philadelphia CTCA hospital purchases BSD-2000 Hyperthermia System

BSD Medical Corporation announced today that the Cancer Treatment Centers of America (CTCA) hospital at Eastern Regional Medical Center, located in Philadelphia, Pennsylvania, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Philadelphia is a state-of-the-art hospital that provides advanced cancer treatments, world-class technologies, and supportive therapies under one roof.

13 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

11 Jan 2011

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.

10 Jan 2011

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

9 Jan 2011

Cancer Treatment News and Research

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

Breastfeeding can partially offset long-term side effects of cancer treatment

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

ETPN, Nanobiotix introduce Nanomed TV to provide information on Nanomedicine

Theraclone, Pfizer enter multi-year research and development collaboration

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Diabetes increases risk of death in breast cancer patients

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

20% of cancer survivors experience chronic pain: Study

Philadelphia CTCA hospital purchases BSD-2000 Hyperthermia System

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

QIAGEN to acquire minority stake in Alacris Theranostics

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Quality of life measures most useful for clinical decision-making in trials with QOL as primary outcome

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Scientists discover new anti-cancer mechanism

Specific silicon microdevices may provide new way to screen metastatic breast cancer cells

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News